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Abstract 
This manuscript contains the conclusion of the consensus meeting on 
the diagnosis of narcolepsy based on the review of Medline publications 
between 1980-2010. Narcolepsy is a chronic disorder with age at onset 
between the first and second decade of life. Essential narcolepsy symptoms 
are cataplexy and excessive sleepiness. Cataplexy is defined as sudden, 
recurrent and reversible attacks of muscle weakness triggered by emotions. 
Accessory narcolepsy symptoms are hypnagogic hallucinations, sleep 
paralysis and nocturnal fragmented sleep. The clinical diagnosis according 
to the International Classification of Sleep Disorders is the presence of 
excessive sleepiness and cataplexy. A full in-lab polysomnography followed 
by a multiple sleep latency test is recommended for the confirmation of 
the diagnosis and co-morbidities. The presence of two sleep-onset REM 
period naps in the multiple sleep latency test is diagnostic for cataplexy-
free narcolepsy. A positive HLA-DQB1*0602 with lower than 110pg/
mL level of hypocretin-1 in the cerebrospinal fluid is required for the 
final diagnosis of cataplexy- and sleep-onset REM period -free narcolepsy.
Descriptors: Cataplexy; Narcolepsy; Diagnosis; Disorders of excessive 
somnolence; Polysomnography 
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Resumo 
Este artigo relata as conclusões da reunião de consenso com médicos 
especialistas sobre diagnóstico de narcolepsia baseada na revisão dos artigos 
sobre narcolepsia listados no Medline entre 1980 e 2010. A narcolepsia é 
uma doença crônica de início entre a primeira e segunda décadas de vida 
do indivíduo. Os sintomas essenciais são cataplexia e sonolência excessiva. 
A cataplexia é definida como episódios súbitos, recorrentes e reversíveis de 
fraqueza da musculatura esquelética desencadeados por situações de conteúdo 
emocional. Os sintomas acessórios são alucinações hipnagógicas, paralisia do 
sono e sono fragmentado. Critérios de diagnóstico clínico de acordo com a 
Classificação Internacional dos Transtornos do Sono são de sonolência excessiva 
e cataplexia. Recomenda-se a realização de polissonografia seguida do teste 
de latência múltipla do sono em um laboratório de sono para confirmação 
e diagnóstico de comorbidades. Quando não houver cataplexia, deve haver 
duas ou mais sonecas com sono REM no teste de latência múltipla do sono. 
Tipagem HLA-DQB1*0602 positiva com níveis de hipocretina-1 abaixo 
de 110pg/mL devem estar presentes para o diagnóstico de narcolepsia sem 
cataplexia e sem sonecas com sono REM.
Descritores: Cataplexia; Narcolepsia; Diagnóstico; Sonolência excessiva; 
Polissonografia; Transtorno do sono 
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Introduction
Narcolepsy is a chronic neurodegenerative and likely auto-
immune disorder characterized by excessive daytime sleepiness 
and dissociative manifestations of REM sleep such as cataplexy, 
sleep paralysis, hypnagogic hallucinations and sleep onset REM 
periods (SOREMP).1 The clinical importance of narcolepsy is 
disproportionate to its prevalence rate because the disorder has 
severe psycho-social and functional impacts. The pathogenesis of 
narcolepsy in humans involves environmental factors and a specific 
autoimmune genetic platform that together lead to hypocretin 
neuronal loss.
1. Epidemiology of narcolepsy
The prevalence of narcolepsy with cataplexy is 15 to 50 cases 
per 100,000 people (0.015% to 0.05%), and the prevalence of 
narcolepsy without cataplexy is 56 cases per 100,000 people 
(0.056%).2-6    
The prevalence of narcolepsy with and without cataplexy is 
estimated at 1.37 per 100,000 people per year,4 with a peak 
incidence in the second decade of life. Narcolepsy affects both 
males and females (1.4-1.8:1).4
2. Genetics of narcolepsy
Both genetic and environmental factors contribute to 
narcolepsy, but alone neither is sufficient or necessary to elicit 
narcolepsy with cataplexy.7 The risk of narcolepsy developing in 
a first-degree relative of a narcoleptic individual is 10 to 40 times 
greater than the risk for the general population. The frequency of 
narcolepsy with cataplexy in first-degree relatives of narcoleptics 
is 2.90% to 3.20%.7 The concordance rate of monozygotic twins 
for narcolepsy with cataplexy is 25% to 31%.7
There is a significant association of narcolepsy with the 
DQB1*0602 allele of the major histocompatibility complex 
(HLA). The prevalence rate of HLA-DQB1*0602 is 88% to 98% 
in the narcoleptic population with cataplexy, 40% to 60% in the 
narcoleptic population without cataplexy, and 12% to 34% in the 
general population8-13 (Table 1). In the southeastern population 
of Brazil, the prevalence of HLA-DQB1*0602 is 13.6% among 
Caucasians14 and 14.30% in Mulattos.15
Recent genome-wide association studies of HLA-DQB1*0602-
positive European Caucasians, healthy Americans, and narcoleptics 
with cataplexy have identified the existence of a polymorphism in 
the T-cell receptor alpha (TRA) gene.16,17 The TRA gene encodes 
a protein that activates cytotoxic CD8 cells and CD4 helper cells, 
resulting in susceptibility to the destruction of hypocretinergic 
HLA-DQB1*0602-positive cells.16,17 These results suggest that 
narcolepsy is an autoimmune disease with HLA haplotype and a 
TRA polymorphism as risk factors. 
Other genes are involved in the genetics of narcolepsy. For 
example, a polymorphism in the catechol-O-methyl-transferase 
(COMT) gene, which encodes the enzyme that inactivates 
dopamine and noradrenaline, influences the manifestation 
of narcoleptic symptoms and the response to treatment with 
modafinil, particularly in females.18,19
3. Symptoms
The two essential symptoms are excessive sleepiness (sensitive, 
but non-specific) and cataplexy (highly specific). Sleep paralysis, 
hypnagogic hallucinations, and fragmented nocturnal sleep are 
considered accessory symptoms. Thus, these five features form 
the classical pentad of narcolepsy symptoms:20-24
• daytime sleepiness; 
• cataplexy; 
• sleep paralysis;
• hypnagogic hallucinations; and
• fragmented nocturnal sleep.
• Other manifestations of narcolepsy are:
• episodes of automatic or stereotypic behaviors;
• nightmares;
• cognitive deficits;
• obesity;
• parasomnias; 
• olfactory deficits;
• type II diabetes.
1) Excessive sleepiness (ES) 
ES is the symptom in 90% to 94% of the cases and is the most 
important complaint made by patients. ES is chronic, daily and 
occurs regardless of how long the patient sleeps during the night.
The main clinical features of ES are:
• sensation of sleepiness of constant or varying intensity, lasting 
one or more hours;
• irresistible sleep attacks despite the attempt to remain awake;
• multiple naps throughout the day which may alleviate 
sleepiness for a few hours in the adult population with narcolepsy;
• the relief of sleepiness provided by naps reflects the intensity of 
background sleepiness and is specific for  differential diagnosis; and
• fluctuations in attention and concentration levels.
2) Cataplexy
Cataplexy is characterized by sudden, recurrent, and reversible 
episodes of skeletal muscle weakness (excluding the diaphragm) 
that occur while awake. Cataplexy attacks are triggered by 
emotional stimuli and are dissociative phenomena of REM sleep 
(wakefulness along with muscular atonia).
Cataplexy is the most specific symptom and it is pathognomonic 
of narcolepsy with low or absent CSF hypocretin-1. Cataplexy 
is the most specific diagnostic marker of narcolepsy. Cataplexy 
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generally emerges simultaneously with ES, although cataplexy 
attacks can appear years later. 
Clinical features of cataplexy attacks are: 
• sudden and recurrent episodes of axial skeletal muscle atonia, 
limb weakness occurs bilaterally;
• the attacks are triggered by situations with strong positive 
emotional content (e.g., laughing) or by fear or anger;
• average duration of a few seconds up to ten minutes;
• consciousness preserved, at least at the beginning of the attack;
hearing and auditory comprehension preserved during the 
attack;
• the attacks end suddenly with return of muscular tone without 
mental confusion or amnesia; and
• breathing during the attack remains normal.
3) Hallucinations
Hypnagogic and hypnopompic hallucinations (HH) are dream-
like experiences occurring in the awake-sleep or sleep-awake 
transitions, respectively. They occur in 20% to 65% of narcoleptics 
and are generally visual or somato-sensorial (i.e., “out of body” 
sensations), but auditory, vestibular or multi-sensorial forms have 
also been described.20-24
Hallucinations can accompany or follow cataplexy and sleep 
paralysis attacks. Terrifying hypnagogic hallucinations occur in 
about 4% to 8% of narcoleptics.
4) Sleep paralysis
Sleep paralysis is the total incapacity to move that occurs when 
falling asleep or when in the transition from sleep into wakefulness. 
The patient remains temporarily incapable of accomplishing 
voluntary acts but awareness is maintained. Sleep paralysis can 
be accompanied by the sensation of inability to breathe and by 
varied hallucinations in up to 50% of cases. Episodes of sleep 
paralysis last from one to ten minutes with an average duration 
of two minutes and ends abruptly after mental effort or by means 
of external sensory stimulation. 
5) Fragmented nocturnal sleep
Multiple awakenings, excessive body movements during sleep, 
and poor sleep quality occur in up to 90% of patients, especially 
in those over 35 years of age. There is no increased total sleep time 
in narcolepsy and no relation between fragmented nocturnal sleep 
and sleepiness severity.20-24
6) Other manifestations of narcolepsy include20-24:
a) Episodes of automatic behaviors and 8% to 40% of cases 
(automatic behaviors with amnesia may occur, ranging from repetitive 
movements to driving a vehicle without awareness of doing it);
b) Cognitive symptoms (narcoleptic individuals present 
attention deficits that become apparent when performing long, 
monotonous, and repetitive psychomotor tasks that are dependent 
on the level of alertness).
4. Ethiopathogenesis of narcolepsy
1) Dysfunction of the hypothalamic hypocretin system
The hypocretinergic system is located in the posterolateral 
perifornical region of the hypothalamus.25 Type 1 and type 2 
hypocretins are excitatory neurotransmitter peptides produced 
exclusively by these hypothalamic cells. The hypocretin system has 
two subpopulations of receptors (hypocretin-1 and hypocretin-2) 
with distinct affinities for the hypocretin peptides.21
The hypocretin system regulates the sleep-wake cycle, feeding 
behaviors, locomotion, reward behavior, autonomic nervous 
system activity, and the hypophysis-pituitary-adrenal axis.21-23
Anatomo-pathological studies in narcoleptic individuals with 
cataplexy show a specific loss of hypocretinergic neurons (Figure 
1). The neuronal loss in narcoleptic individuals with cataplexy 
is selective, affecting only hypocretinergic cells and sparing the 
adjacent neighboring neurons that contain melanin concentrating 
hormone (MCH), which co-localize with hypocretinergic cells.25 
2) Narcolepsy-cataplexy and hypocretins
Hypocretin deficiency engenders a state of disorganization and 
instability of sleep and wakefulness states. Excessive sleepiness, 
intrusions of sleep into wakefulness and of wakefulness during 
sleep (nocturnal sleep and naps), fragmented sleep, and 
innumerable transitions between sleep-wake-sleep have been 
reported. Dissociative phenomena of REM sleep – cataplexy, 
sleep paralysis, hypnagogic hallucinations, and REM sleep 
without atonia (RWA) have also been reported in subjects with 
narcolepsy.20-24   
3) Autoimmune hypothalamic lesions and narcolepsy
Data supporting the autoimmune etiology of sporadic 
idiopathic narcolepsy-cataplexy:
• the presence of HLA-DQB1*0602 and polymorphism in the 
T-cell receptor alpha (TRA) gene confer a genetic susceptibility 
risk for the development of irreversible and selective post-natal 
injury to hypocretinergic neurons;17,26,27 
• narcolepsy sporadically co-occurs with multiple sclerosis, also 
an autoimmune illness associated with HLA-DQB1*0602;
• there is an association between narcolepsy and autoimmune 
paraneoplastic syndromes, such as limbic encephalitis, with anti-
Ma2 antibodies;22-24,27
• there is no clinically significant progression of symptoms, a 
fact incompatible with a neurodegenerative illness with progressive 
neuronal loss;22-24,27
• some patients even experience an improvement of symptoms 
with time, which is suggestive of a non-degenerative illness;22-24,27
• in some cases of recent-onset narcolepsy patients had elevated 
anti-streptolysin O (ASLO) titers, suggestive of recent streptococci 
infection. Such an infection could be an environmental trigger 
of an autoimmune reaction mediated by T-cell receptor alpha 
lymphocytes with antibodies against hypocretin cells;26
• there is selective destruction of hypocretinic neurons, sparing 
the Melanin-Concentrating-Hormone (MCH) positive cells 
located in the same anatomical region as hypocretin neurons;27 
• intravenous administration of immunoglobulin G produces 
partial clinical response in some cases of recent-onset narcolepsy;26
• narcoleptic dogs present partial response to traditional 
immunosuppressant agents, such as methotrexate, azathioprine or 
prednisone, thereby delaying the onset of the disease.26-27
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5. Complications 
1) Quality of life and social, academic, and professional 
performance
Daytime sleepiness is the main cause of poor quality of life and 
cataplexy is an important limiting factor in the functioning of the 
narcoleptic individual.28,29 Unlike other neurological conditions 
that affect sleep such as Parkinson’s disease and obstructive sleep 
apnea syndrome, narcolepsy (and the side effects of its treatment) 
occur at an early age, impairing the patient during the period of 
academic learning and development of personality.28,29
Professional difficulties such as low income, loss of promotions, 
layoffs, unemployment, and especially academic dysfunction 
occur as a result of narcolepsy.28,29 Side effects of narcoleptic 
medications such as orthostatic hypotension, dry mouth, and 
erectile dysfunction are additional setbacks that impair quality 
of life.28,29 
2) Risk of automobile and industrial accidents 
Excessive sleepiness increases the risk of automobile and 
industrial accidents specifically in the population under 40 years 
of age. In a driving-simulation test, narcoleptics were significantly 
more error-prone and the number of errors progressively increased 
throughout the duration of the test.30,31
6. Comorbidities
1) Depression
Between 18% and 57% of patients with narcolepsy are reported to 
have symptoms of depressed mood, loss of interest, and anhedonia; 
however, the prevalence of depression among narcoleptics is equal 
to that of the general population.32 The reduction in quality of life 
due to diurnal sleepiness, isolation and social impairment and the 
cognitive deficits that occur in narcoleptics are key factors for the 
development of depressive symptoms.32 
2) Anxiety
The prevalence of anxiety symptoms, panic attacks, and social 
phobia is about 25% and occur regardless of age and of the 
duration of the clinical treatment.32 Anxiety, panic attacks, and 
social phobia are reasonable consequences of the chronic nature 
of the disease and are examples of the limitations imposed by 
narcolepsy onto the patients’ social and professional outcomes. 32 
3) REM sleep behavior disorder (RBD)
The prevalence of RBD among narcoleptic patients ranges 
between 36% and 61%. 
RBD in narcoleptic patients is clinically different from RBD 
not associated with narcolepsy. Among narcoleptics, RBD onset 
occurs earlier in life (about 31 years of age) and with slightly 
higher rates among men. There is no evidence that RBD associated 
with narcolepsy represents a risk factor for the development of 
neurodegenerative conditions.33-37
4) Eating disorders
The prevalence of compulsive eating and restrictive eating 
behaviors is greater in the population with narcolepsy than in 
the general population.38 The symptoms of eating disorders do 
not correlate with medication use or with affective symptoms.38 
5) Obesity
Obesity is more prevalent in patients with early-onset narcolepsy 
and in patients with more intense sleepiness, regardless of the use of 
medications. Obesity in the narcolepsy population is of the central 
type. The body mass index of narcoleptics is 10% to 20% higher than 
that of normal controls.39 The causes of obesity might be related to 
the hypocretinergic neurotransmission, autonomic nervous system 
activity, basal metabolism, and the leptin-ghrelin system that is 
responsible for signaling caloric need, appetite, and satiety.39-41 
6) Obstructive sleep apnea syndrome (OSAS)
The prevalence of OSAS is higher in the narcoleptic population 
(prevalence rates from 9% to 19%) than in the general 
population.42 
7) Migraine
The prevalence of migrainous headaches in women and 
men affected by narcolepsy with cataplexy is 44% and 28%, 
respectively. The prevalence of migraines is greater in the 
narcoleptic subpopulation with more intense symptoms.43,44 
8) Narcolepsy and multiple sclerosis
Narcolepsy and multiple sclerosis (MS) are both commonly 
associated with mutations of the HLA 0602 allele, and both are 
considered autoimmune disorders. Multiple sclerosis is a risk factor 
for narcolepsy, but the opposite is not true.45
  
7. Differential diagnosis
1) The differential diagnosis of ES includes:1,46 
• behaviorally-induced insufficient sleep syndrome;
• obstructive sleep apnea syndrome;
• idiopathic hypersomnia of the central nervous system; 
• hypersomnia associated with central nervous system disorders; 
• hypersomnia due to associated medical conditions;
• hypersomnia associated with drugs or other substances; 
• recurrent hypersomnia; and
• circadian rhythm alterations.
The presence of cataplexy and secondary symptoms, the age 
at onset, and the characteristics of naps are important for the 
differential diagnosis. 
2) Behaviorally-induced insufficient sleep syndrome
Voluntary chronic deprivation of sleep generates more constant 
ES symptoms and in contrast with the irresistibility of narcolepsy 
sleep attacks, patients with insufficient sleep syndrome wish to 
sleep. Naps are long and relieving and ES disappears. The diagnosis 
is reached through the medical history, a sleep diary, and by the 
length of the sleep period.46 
3) Obstructive sleep apnea syndrome (OSAS)
OSAS and narcolepsy can coexist due to the frequency of 
central-type obesity in the two conditions. The diagnosis is made 
through the medical history, polysomnography, and a multiple 
sleep latency test. The sleep fragmentation caused by apnea may 
mimic the classic narcolepsy changes in the polysomnography 
and in the multiple sleep latency test. Eventually, the definitive 
diagnosis can be reached only when OSAS treatment unmasks 
the sleepiness caused by narcolepsy.46
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4) Idiopathic hypersomnia of the central nervous system 
Distinguishing between narcolepsy without cataplexy and 
idiopathic sleepiness of the CNS is intrinsically difficult.1,45 
Narcolepsy naps are short, refreshing, occur in the form of attacks, 
and are not preceded by a significant degree of sleepiness. Idiopathic 
hypersomnia naps are long, non-restorative and preceded by a 
long-standing sleepiness sensation. Long, non-restorative nocturnal 
sleep (> 10 hours), morning fatigue upon waking, and episodes 
of sleep-drunkenness with mental confusion are characteristic of 
idiopathic hypersomnia rather than narcolepsy. Classic REM sleep 
abnormalities in polysomnography and the multiple sleep latency 
test do not usually occur in idiopathic hypersomnia of the CNS.1,47 
5) Recurrent hypersomnia
Excessive sleepiness can occur in recurrent hypersomnia as 
in Kleine-Levin syndrome that is characterized by self-limited 
outbreaks lasting between 8 and 15 days associated with sleepiness, 
hyperphagia, copropraxia, coprolalia, and hypersexuality.48 
6) Differential diagnosis of cataplexy
Medical conditions with episodes that mimic recurrent cataplexy 
attacks are very rare. Some findings that are present during a 
cataplexy attack and that significantly assist in the differential 
diagnosis are:
• Deep tendon areflexia during the transient attack;
• preservation of consciousness;
• absence of amnesia; 
• maintenance of the auditory capacity and understanding 
during the attack;
• attacks triggered by laughter, excitement or fright; and
• sudden ending of the attack without amnesia or mental 
confusion.
7) Cataplexy and epilepsy
Cataplexy and sleep paralysis can be confounded with the 
diagnosis of astatic- or akinetic-type epileptic seizures.49,50
8) Cataplexy and gelastic seizures
Despite the occurrence of laughter during gelastic seizures and 
the relationship between laughter and cataplexy, there is no loss of 
neuromuscular tone or mental confusion during gelastic seizures.50 
9) Hereditary diseases with isolated cataplectic-type attacks
Cataplexy attacks can occur in Type C Niemann-Pick 
disease, Norrie disease, Coffin Lowry syndrome, and Moebius 
syndrome.23,51
10) Pseudo-cataplexy 
Pseudo-cataplexy is the simulation of cataplexy attacks by 
narcoleptic patients to acquire access to stimulant medication or 
some other form of compensation.52  
11) Differential diagnosis of hallucinations in narcolepsy
a) Schizophrenia
Hallucinations in schizophrenia are mainly auditory, occurring 
while awake, while narcoleptic hallucinations are visual and 
assume the form of figures, shadows, and seeing in black and 
white and occur during transitions between sleep and waking.53 
The narcoleptic patient does not believe that the visions are 
hallucinations.54
12) Differential diagnosis of sleep paralysis
The prevalence of sleep paralysis in the general population 
is 2.5% to 40%. Sleep paralysis can be associated with the use 
of anxiolytic medication, medical illness, bipolar disorder, and 
unrestored sleep. 55 
8. Narcolepsy secondary to medical or neurological 
illnesses 
More than 90% of narcolepsy cases are sporadic. Familial cases 
and cases of secondary narcolepsy are rare.7 Secondary narcolepsy 
is associated with hypothalamic disorders, such as Type C 
Niemann-Pick disease, tumors, cranial trauma, multiple sclerosis, 
post-encephalitis, agenesis of the corpus callosum, sarcoidosis, 
neuro-cysticercosis, and limbic encephalitis. Narcolepsy-cataplexy 
is not associated with reduced hypocretin-1 levels in the CSF. 
In contrast, about 20% of head trauma cases are followed by 
chronically reduced CSF hypocretin-1 levels. Only a minority of 
TCE cases develop post-traumatic narcolepsy-cataplexy with PSG 
and MLST changes.45,56 
9. Laboratory diagnosis of narcolepsy
1) Neurophysiological evaluation
The full neurophysiological evaluation of narcolepsy requires a 
hospital-based in-lab polysomnography (PSG) followed, on the 
next day, by the multiple sleep latency test (MSLT).1 These tests 
must be completed under supervision of qualified technical staff 
and a qualified medical doctor56,57 and require technical accuracy 
to avoid false negative or false positive results.58 The following 
steps should be taken to ensure optimal sleep studies:
• discontinuation of all REM sleep-suppressing agents such 
as antidepressants (tricyclics, monoamine oxidase inhibitors, 
etc.) and CNS stimulants. The use of these medications must be 
suspended for a period of 14 days before the sleep studies (6 weeks 
in the case of fluoxetine);
• stop all sedatives, hypnotics, and antihistamine agents at least 
one week before the tests;
• reduce or remove stimulating substances such as caffeine and 
nicotine during the week preceding the examination; and
• maintain regular sleep-wakefulness schedules and sleep at least 
six hours per night during the two weeks prior to the sleep studies.
2) Polysomnography
a) Indication of PSG in narcolepsy
Polysomnography followed by the MSLT is mandatory for 
laboratory diagnosis in cases of narcolepsy without cataplexy (see 
below). In cases of well-characterized narcolepsy with cataplexy, 
PSG is still necessary for the diagnosis of comorbidities.59  
Interpretation of PSG findings
The most frequent narcolepsy findings are:60-62
• normal sleep efficiency in younger patients;
• non-REM sleep latency below 10 minutes;
• reduction of REM sleep latency below 70 minutes;
• increased number of micro-arousals;
• increased transitions between sleep and waking stages;
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• increased awake time after sleep onset (WASO); and
• increase of stage 1 sleep.
Other significant PSG findings include:  
• increased eye movements during REM sleep; 
• REM sleep without atonia (REMSWA); and 
• increased phasic activity in the electroencephalogram (EEG). 
These findings are more prevalent in the narcoleptic population 
than in the general population.34,63,64 
3) Multiple sleep latency test
The MSLT must be performed according to the guidelines 
defined by the American Academy of Sleep Medicine task force.65 
A PSG carried out the night preceding the MSLT is necessary to 
document the nocturnal sleep quantity and to evaluate the sleep 
architecture.65 The MSLT consists of five opportunities to sleep, 
taken every two hours during the main waking period. 
a) MSLT indications
The MSLT is indicated for diagnostic confirmation in all 
patients who are suspected to have narcolepsy without cataplexy.65 
b) Interpretation of the MSLT
An average sleep latency less than or equal to eight minutes with 
the presence of two or more REM sleep episodes is sufficient for 
the MSLT diagnosis of narcolepsy.1  
The MSLT sensitivity and specificity are, respectively, 0.78 
and 0.93 when using a cut-off point of two or more SOREMP 
episodes.65 A negative MSLT for narcolepsy does not definitively 
discard the diagnosis.65,66
The SOREMP do not only occur in narcolepsy, it is thus 
important to consider and/or treat other illnesses before using 
the finding of SOREMP to support a narcolepsy diagnosis. Sleep 
fragmentation associated with OSA can cause false-positive results 
in the MSLT.65,66
c) Indications for MSLT repetition in narcolepsy:67
• first test affected by external circumstances or inadequate 
study conditions;
• ambiguous results (for example, only one SOREMP); and
• clinical suspicion of narcolepsy despite one or more previous 
negative MSLTs. 
4) Maintenance of Wakefulness Test (MWT)
The MWT consists of a diurnal evaluation that measures one’s 
capacity to remain awake in an environment with little sensory 
stimulation.68,69 It is not a diagnostic test for narcolepsy and the 
American Academy of Sleep Medicine recommends the MWT to 
evaluate65 the capacity of a patient to remain awake when there 
is a safety risk to the patient or others66,67 and to determine the 
response to treatment in patients with ES 66,67
5) Conclusions of the neurophysiological evaluation
The PSG and MSLT are useful to confirm the narcolepsy 
diagnosis. If PSG followed by the MSLT is negative on separate 
occasions, the diagnosis of ES due to narcolepsy is excluded.
6) Subjective evaluation of ES
The most widely used scale for the clinical evaluation of ES is 
the Epworth Sleepiness Scale70 (Table 2). Values above 10 points 
are considered abnormal.71,72
Immuno-genetics and HLA-DQB1*0602 typing  
Of the cases of narcolepsy with cataplexy, 88% to 98% are HLA-
DQB1*0602 antigen positive.7,12,13,73 However, the presence of this 
allele is not a sufficient or necessary factor for the development 
of narcolepsy.7,73 In the general population, the prevalence of the 
HLA-DQB1*0602 antigen varies between 12% and 34%8,14,15 
(Table 1). In narcolepsy without cataplexy, the HLA-DQB1*0602 
prevalence rate is 40% to 60%. 8,9 HLA typing therefore possesses 
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low specificity in cases of narcolepsy without cataplexy and alone 
it is not sufficient to diagnose narcolepsy without cataplexy.46,74 
A positive HLA is a diagnostic support criterion, but its absence 
does not eliminate the presence of narcolepsy without cataplexy. 
In conclusion, the clinical use of the HLA-DQB1*0602 allele 
for the purpose of diagnosing narcolepsy is limited because 
it possesses low sensitivity and specificity in patients without 
cataplexy 46,74 
Hypocretin type 1 in the CNS 
The normal CSF hypocretin concentration is over 200pg/mL in 
all ages and across genders.75-78 Hypocretin-1 levels below 110pg/
mL are highly specific (99%) and sensitive (87-89%) for narcolepsy 
cases with cataplexy, but not sensitive for cases without cataplexy 
(Table 1). However, because 16% of the cases of narcolepsy 
without cataplexy are accompanied by lumbar hypocretin-1 levels 
above 110pg/mL, this finding does not exclude the diagnosis 
of narcolepsy without cataplexy.79-81 A strong association exists 
between hypocretin-1 reduction in the CSF with the presence of 
cataplexy and positive HLA-DQB1*0602 haplotype.13 
The measurement of hypocretin type 1 levels in the CSF is 
indicated in the following situations for the purpose of diagnosing 
sporadic narcolepsy:
• individuals with ES with one or more negative MSLT tests;
• when there are doubts regarding the existence of cataplexy; 
• use of medication that is active in the CNS and could interfere 
with MSLT results; 
• young patients (children and adolescents) without cataplexy; 
and
• patients who cannot complete the MSLT due to operational 
reasons.
In the situations above, HLA-DQB1*0602 typing must precede 
the measurement of hypocretin type 1 levels in the CSF. If HLA-
DQB1*0602 is negative, it becomes unnecessary to measure 
hypocretin levels because there is no reduction of hypocretin type 
1 in the CSF without HLA-DQB1*0602 positivity46,74 in cases 
of sporadic narcolepsy. 
Conclusion
It is the intention of the authors that the data presented herein 
will serve to help the growing number of health professionals 
establish accurate narcolepsy diagnoses, thus enabling the 
determination of the most adequate treatment. Perhaps, in future 
studies, the data herein will also serve the purpose of elucidating 
yet unknown mechanisms that underlie the complex chemical 
orchestrations that govern sleep.
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